Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
4期
已完成
NCT05548647
| 适应症 | Obesity |
|---|
| 分期 | 4期 |
|---|
| 申办方 | University of Pennsylvania |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 120 人 |
|---|
| 干预（药物） | Behavioral Treatment, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY] |
|---|
| 开始日期 | 2022年7月26日 |
|---|
| 完成日期 | 2025年5月12日 |
|---|
| 结果公布日 | 2026年8月3日 |
|---|
摘要
This study will evaluate the effect of semaglutide on eating behavior, appetite (hunger/fullness), and food liking in the long-term, as compared to placebo. All participants will receive lifestyle modification (diet and exercise) counseling, and will be prescribed the FDA-approved weight loss medication, semaglutide, or placebo (an inactive saline solution) for 72 weeks.
Study 1 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast)
S1: Change from baseline to weeks 20, 40, and 60 · kcal
| Behavioral Treatment + Placebo (Weeks 0-60) | -75.1 ± 52.6 kcal |
|---|
| Behavioral Treatment + Medication (Weeks 0-60) | -367.0 ± 37.2 kcal |
|---|
| Behavioral Treatment + Placebo (Weeks 0-60) | -76.8 ± 73.8 kcal |
|---|
| Behavioral Treatment + Medication (Weeks 0-60) | -317.0 ± 49.7 kcal |
|---|
| Behavioral Treatment + Placebo (Weeks 0-60) | 69.6 ± 73.9 kcal |
|---|
| Behavioral Treatment + Medication (Weeks 0-60) | -200.0 ± 50.1 kcal |
|---|
| p-value | <0.0001 |
|---|
| Mean Difference (Net) | 291.9 (95% CI 164.0–419.8) |
|---|
Study 2 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast)
S2: Endpoint comparison at week 72 · kcal
| Continuous Placebo (Weeks 60-72) | 1073.0 ± 71.1 kcal |
|---|
| Medication (Semaglutide) Switched to Placebo (Weeks 60-72) | 951.8 ± 42.9 kcal |
|---|
| Continued Medication (Semaglutide) (Weeks 60-72) | 657.7 ± 81.5 kcal |
|---|
| p-value | 0.1513 |
|---|
| Mean Difference (Final Values) | 121.2 (95% CI -46.0–288.4) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。